TEMPE Ariz — Arizona Cardinals rookie safety Deo

first_imgTEMPE, Ariz. — Arizona Cardinals rookie safety Deone Bucannon has all of the physical tools necessary to be successful on the field in the NFL. The Cardinals’ first-round draft pick also knows that doesn’t mean anything when it comes to playing at football’s highest level. “Everyone out here has the physical tools to be a great player; it’s just a matter of who’s going to be smarter,” Bucannon said Tuesday after the team’s first minicamp practice. “That’s my goal, to be the smartest player out there. I want to learn the playbook the best I can.” The 5: Takeaways from the Coyotes’ introduction of Alex Meruelo Bucannon has plenty of experience with what it takes to be successful on the football field. He was named a first-team All-American and first-team All-Pac-12 in his final season at Washington State, and he led the conference in both interceptions and tackles. But the 6-foot-1, 208-pounder didn’t rack up those stats purely through physical ability — though he has plenty of that, too. Bucannon said he prides himself on being one of the smartest players on the field, and that’s something he expects to continue into his NFL career. “There’s always room for improvement,” he said. “I understand the defense, now I want to take it to the next level. I want to be a playmaker.”Cardinals coach Bruce Arians said Bucannon took an important step Tuesday after missing time with a foot injury during OTAs last week, adding that “he needs it, psychologically, just to get out there to play.”Bucannon’s knowledge of the game and ability to quickly understand schemes and concepts hasn’t gone unnoticed on teammates — particularly ones he’ll share a defensive backfield with. “He can do it all,” safety Rashad Johnson said. “He’s a very smart guy and I’m looking forward to what he’s going to do this year.” Top Stories Former Cardinals kicker Phil Dawson retires Derrick Hall satisfied with D-backs’ buying and selling Comments   Share   Grace expects Greinke trade to have emotional impact And if Bucannon has his way, Johnson will have a lot to enjoy watching in 2014. “I expect a lot out of myself,” Bucannon said, “and I’m going to get a lot out of myself.” – / 11last_img read more

Antibacterial substance found in toothpaste may fight against lifethreatening lung disease

first_imgMay 17 2018A common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis, or CF, when combined with an already FDA-approved drug.Michigan State University researchers have found that when triclosan, a substance that reduces or prevents bacteria from growing, is combined with an antibiotic called tobramycin, it kills the cells that protect the CF bacteria, known as Pseudomonas aeruginosa, by up to 99.9 percent.CF is a common genetic disease with one in every 2,500 to 3,500 people diagnosed with it at an early age. It results in a thick mucus in the lungs, which becomes a magnet for bacteria.These bacteria are notoriously difficult to kill because they are protected by a slimy barrier known as a biofilm, which allows the disease to thrive even when treated with antibiotics.”The problem that we’re really tackling is finding ways to kill these biofilms,” said Chris Waters, lead author of the study and a microbiology professor.According to Waters, there are many common biofilm-related infections that people get such as ear infections and swollen, painful gums caused by gingivitis. But more serious, potentially fatal diseases join the ranks of CF including endocarditis, or inflammation of the heart, as well as infections from artificial hip and pacemaker implants.The research is published in the journal Antimicrobial Agents and Chemotherapy.Waters and his co-authors, Michael Maiden and Alessandra Hunt, grew 6,000 biofilms in petri dishes, added in tobramycin along with many different compounds, to see what worked better at killing the bacteria. Twenty-five potential compounds were effective, but one stood out.”It’s well known that triclosan, when used by itself, isn’t effective at killing Pseudomonas aeruginosa,” Hunt said, a post-doctoral associate of microbiology and molecular genetics. “But when I saw it listed as a possible compound to use with tobramycin, I was intrigued. We found triclosan was the one that worked every time.”Related StoriesNew methods to recognize antimicrobial resistant bacteria and how they workNew research links “broken heart syndrome” to cancerGene modulation goes wireless hacking the “boss gene”Triclosan has been used for more than 40 years in soaps, makeup and other commercial products because of its antibacterial properties. Recently, the FDA ruled to limit its use in soaps and hand sanitizers due to insufficient data on its increased effectiveness and concern that it was being overused. Clear evidence has shown, though, that its use in toothpaste is safe and highly effective in fighting gingivitis, and it is still approved for use.”Limiting its use is the right thing to do,” Maiden said, a graduate student in medicine. “The key is to avoid creating resistance to a substance so when it’s found in numerous products, the chances of that happening increase.”Tobramycin is currently the most widely used treatment for CF, but it typically doesn’t clear the lungs of infection, Waters said. Patients typically inhale the drug, yet find themselves chronically infected their whole lives, eventually needing a lung transplant.”Most transplants aren’t a viable option though for these patients and those who do have a transplant see a 50 percent failure rate within five years,” he said. “The other issue is that tobramycin can be toxic itself.”Known side effects from the drug include kidney toxicity and hearing loss.”Our triclosan finding gives doctors another potential option and allows them to use significantly less of the tobramycin in treatment, potentially reducing its use by 100 times,” Hunt said.Within the next year, Waters and his colleagues will begin testing the effectiveness of the combination therapy on mice with hopes of it heading to a human trial soon after since both drugs are already FDA approved.Just brushing your teeth with toothpaste that has triclosan won’t help to treat lung infections though, Maiden said.”We’re working to get this potential therapy approved so we can provide a new treatment option for CF patients, as well as treat other biofilm infections that are now untreatable. We think this can save lives.”Source: https://msutoday.msu.edu/news/2018/ingredient-in-your-toothpaste-may-combat-severe-lung-disease/last_img read more